Zika response in full gear

Efforts to combat the outbreak yielded diagnostics and first vaccine trials

Lisa M. Jarvis
As travel advisories for pregnant women multiplied, combating the Zika virus was a top priority this year for both government agencies and the drug industry.

Zika by the numbers“This is the most complicated emergency the CDC has ever handled,” Anne Schuchat, principal deputy director of the Centers for Disease Control & Prevention, told reporters last month at the American Society for Tropical Medicine & Hygiene’s annual meeting. It’s the first time the world has seen a mosquito-borne virus that can be spread sexually or cause birth defects. Moreover, “we have not got a great track record with controlling Aedes aegypti mosquitos,” she said.

The public did get some good news last month when the World Health Organization declared that Zika is no longer a public health emergency. And while health experts stress that efforts to address the virus must continue at full speed, government agencies, health groups, and industry have made some headway in figuring out how to combat it.

Prior to the outbreak, there was no FDA-approved test to screen for the virus, which can be difficult to distinguish from dengue, a more common flavivirus. Since February, FDA has issued emergency use authorizations for 12 diagnostic tests.

Ann Powers, chief of CDC’s Alphavirus Laboratory, noted at the tropical medicine meeting that they can be improved. For example, available tests can confirm the virus in about five days; researchers would like to trim that to 36 to 48 hours.

Although a Zika vaccine wasn’t on anyone’s radar prior to the outbreak, three have sped into human trials. Safety studies are ongoing for a purified, inactivated virus vaccine called ZPIV, which was developed by Walter Reed Army Institute of Research, as well as DNA vaccines developed by the National Institute of Allergy & Infectious Diseases and Inovio Pharmaceuticals.

Meanwhile, research into combating the mosquitos themselves continues to lag. “We’ve been very negligent” in finding new ways to control viral vectors, Powers noted. Priorities include the development of new pesticides, studies to determine whether existing pesticides are still effective, and implementing a systemic process for sharing information on the emergence of viral vectors.

“It’s critical not only to Zika, dengue, and chikungunya,” she said, “but whatever might come next—and something will come next.”

Leave a comment

Comments (1)

  • ReplyLabs made advances in Zika research | C&EN December 12, 2016

    […] remains to protect pregnant women and their unborn babies, there’s cause for cautious optimism: A dozen diagnostic tools to identify the pathogen and several Zika vaccines are currently being tested on humans in the […]